Advertisement
Advertisement
TWST
Twist Bioscience Corporation Common Stock
49.11
USDSponsored
+1.44
+3.02%
Feb 13, 15:59 UTC -5
Closed
Pre-Market
48.54
-0.57
-1.16%
TWST Earnings Reports
Positive Surprise Ratio
TWST beat 18 of 30 last estimates.
60%
Next Report
Date of Next Report
May 04, 2026
Estimate for Q2 26 (Revenue/ EPS)
$109.83M
/-$0.48
Implied change from Q1 26 (Revenue/ EPS)
+5.92%
/-4.00%
Implied change from Q2 25 (Revenue/ EPS)
+18.36%
/-27.27%
Twist Bioscience Corporation Common Stock earnings per share and revenue
On Feb 02, 2026, TWST reported earnings of -0.50 USD per share (EPS) for Q1 26, missing the estimate of -0.43 USD, resulting in a -14.00% surprise. Revenue reached 103.70 million, compared to an expected 102.82 million, with a 0.86% difference. The market reacted with a +13.98% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 11 analysts forecast an EPS of -0.48 USD, with revenue projected to reach 109.83 million USD, implying an decrease of -4.00% EPS, and increase of 5.92% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Vertex Pharmaceuticals Inc
Report Date
Feb 12, 2026 For Q4 25
Estimate
$5.17
Actual
$5.03
Surprise
-2.79%
Alnylam Pharmaceuticals, Inc.
Report Date
Feb 12, 2026 For Q4 25
Estimate
$1.14
Actual
$0.82
Surprise
-28.48%
Exact Sciences Corp
Report Date
Feb 13, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.38
Surprise
-462.13%
Moderna, Inc. Common Stock
Report Date
Feb 13, 2026 For Q4 25
Estimate
-$2.69
Actual
-$2.11
Surprise
+21.72%
Benitec Biopharma Inc. Common Stock
Report Date
Feb 12, 2026 For Q2 26
Estimate
-$0.22
Actual
-$0.26
Surprise
-14.14%
Rezolute, Inc. Common Stock (NV)
Report Date
Feb 12, 2026 For Q2 26
Estimate
-$0.19
Actual
-$0.22
Surprise
-15.36%
Citius Oncology, Inc. Common Stock
Report Date
Feb 13, 2026 For Q1 26
Estimate
$0.06
Actual
-$0.06
Surprise
-198.04%
Grace Therapeutics, Inc. Common Stock
Report Date
Feb 12, 2026 For Q3 26
Estimate
-$0.28
Actual
-$0.14
Surprise
+50.98%
Pluri Inc. Common Stock
Report Date
Feb 12, 2026 For Q2 26
Estimate
-$0.66
Actual
-$0.71
Surprise
-7.09%
Edesa Biotech, Inc. Common Shares
Report Date
Feb 13, 2026 For Q1 26
Estimate
-$0.45
Actual
-$0.28
Surprise
+39.00%
FAQ
What were Twist Bioscience Corporation Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Twist Bioscience Corporation Common Stock reported EPS of -$0.50, missing estimates by -14%, and revenue of $103.70M, 0.86% above expectations.
How did the market react to Twist Bioscience Corporation Common Stock's Q1 2026 earnings?
The stock price moved up 13.98%, changed from $41.07 before the earnings release to $46.81 the day after.
When is Twist Bioscience Corporation Common Stock expected to report next?
The next earning report is scheduled for May 04, 2026.
What are the forecasts for Twist Bioscience Corporation Common Stock's next earnings report?
Based on 11
analysts, Twist Bioscience Corporation Common Stock is expected to report EPS of -$0.48 and revenue of $109.83M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement